The effect on ciprofloxacin's bioavailability (F) of calcium carbonate given 2 h before ciprofloxacin administration in 12 male volunteers was studied. The relative F with calcium was 0.98, maximum concentration of drug in serum increased significantly from 1.98 to 2.42 mg/liter (P = 0.039), and time to maximum concentration of drug in serum decreased from 1.82 to 1.26 h (P = 0.038). Thus, a single calcium carbonate dose, administered 2 h before ciprofloxacin, does not alter the F of this quinolone.
Ciprofloxacin is an orally administered broad-spectrum antibiotic with activity against multiply drug-resistant organisms (19) . All quinolones are subject to several drug-drug interactions affecting absorption, such as the formation of inactive quinolone-chelate complexes with various cations (17) . Magnesium-or aluminum-containing antacids may almost completely inhibit ciprofloxacin absorption (6) , and patients taking these antacids should use an alternative antibiotic class (11) or have a 2-h interval between doses of cation-containing antacids and quinolones (2) . Calcium (18) , iron (16) , and zinc (16) have also been found to decrease the bioavailability (F) of coadministered ciprofloxacin. Sucralfate may also reduce the absorption of quinolones (12, 14) , probably by releasing aluminum in the gastrointestinal tract.
A recent study documented the frequencies of coadministration patterns of ciprofloxacin and cations (10) . The significance of the interaction between calcium and ciprofloxacin is controversial, and reports are conflicting (4, 5, 13) . The effects of spaced-interval dosing of calcium supplements and ciprofloxacin have not been evaluated. We therefore studied the effects of a 2-h interval between doses of calcium carbonate and ciprofloxacin on the F of ciprofloxacin.
This study was approved by the Institutional Review Board. Written, informed consent was obtained from all participants. Inclusion criteria were as follows: subjects were male, between 18 and 70 years of age, and in good health as determined by medical history. Exclusion criteria were current therapy with any medication within 2 weeks prior to the study, a history of drug allergy, alcoholism or drug abuse, psychiatric or seizure disorders, and thyroid or pulmonary disease. The mean age + standard deviation of our 12 volunteers recruited was 33.4 + 6.3 years (range, 21 to 43 years), and their mean weight + standard deviation was 77.8 + 7 kg (range, 60 to 118 kg). One volunteer weighed more than 20% over his ideal body weight.
The study design was a nonblinded crossover, in which each individual served as his own control, and consisted of two phases. On the morning of each phase, an indwelling peripheral venous catheter was placed for blood sampling and was kept patent with 2 ml of heparin flush (10 U/ml). On * Corresponding author. the morning of phase 1, each individual received a single 500-mg dose of ciprofloxacin (Cipro; Miles Laboratories, Inc., West Haven, Conn.) with approximately 100 ml of water. Blood samples (5 ml) were drawn prior to administration and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 h after administration of the dose. Seven days later, a single 500-mg dose of elemental calcium (as calcium carbonate, 1,250-mg tablets; Roxane Laboratories, Inc., Columbus, Ohio) was administered 2 h prior to a single 500-mg dose of ciprofloxacin. Volunteers were required to fast from 12 h prior to until 2 h after ciprofloxacin ingestion. Water ingestion was not restricted. Blood samples were collected as described above. Blood (5 ml) was withdrawn from the catheter and discarded before each 5-ml sample was drawn. The blood sample was allowed to clot, and the serum was separated by centrifugation within 1 h of collection. The serum was frozen at -20°C until assayed. All ciprofloxacin and calcium doses were obtained from the same lot of each agent.
Ciprofloxacin concentrations in serum were assayed by using a previously described high-pressure liquid chromatography (HPLC) method (8) . Two separate but overlapping serum standard curves were prepared (5.0 to 0.125 and 1.0 to 0.02 mg/liter). Coefficients of correlation were >0.999. Within-run reproducibility was assessed by using spiked serum (n = 10) at 3 and at 0.25 mg/liter. Correlation coefficients were 2.3 and 3.1%, respectively. Between-run reproducibility was assessed with a pooled-serum sample with an assay value of 0.49 mg/liter for both the high and the low range. Coefficients of variation between days were 3.4% (high range, n = 13) and 3.7% (low range, n = 14).
Areas under the ciprofloxacin serum concentration-time curve (AUCs) were calculated both from a noncompartmental model, by using a trapezoidal method, and from data fitted to a two-compartment linear model, by using the RSTRIP program (MicroMath Scientific Software, Salt Lake City, Utah). The AUCs from time zero to the last measured concentration (AUCO12) and the extrapolated AUC from time zero to infinity (AUC,,) were calculated from both methods. AUC., was calculated by using the last measured concentration in serum for the compartmental model. For the noncompartmental model, the assumption was made that the last three measured concentrations were linear, and the elimination rate constant (kel) was calculated from these NOTES 1005 data. The AUC,C was calculated by using this value of ke1
and the last measured concentration. In addition, the time to peak concentration of drug in serum (Tma.), peak concentration in serum (Cm.j), half-life of elimination (t112.), and k., were determined from both methods and for both phase 1 (without calcium) and phase 2 (with calcium). For the noncompartmental model, Cmax and Tmax were both determined as the time to the highest measured concentrations. For compartmental data, these values were obtained from visual inspection of the fitted curve. The means and standard deviations of each of these pharmacokinetic parameters were determined, and the differences between them for phases 1 and 2 were determined by using a two-tailed Student's t test. A probability of less than 5% was taken as statistically significant. The relative F of ciprofloxacin under the potential influence of calcium was calculated as AUCPHASE 2/AUCPHASE 1. F was calculated for each individual by using AUCs from both compartmental and noncompartmental models, and the mean values of F were reported. Calculated ciprofloxacin pharmacokinetic parameters for each subject are shown in Tables 1 and 2 for compartmental and noncompartmental models, respectively. acin averages approximately 70%, but a highly variable F is noted when repeated doses are administered to the same individual (15) . Our results also demonstrated a highly variable intersubject F, with similar numbers of subjects having higher and lower values of F, and are similar to those reported by Crump et al. (3) . Two subjects, numbers 5 and 10, had high and low values of F, respectively. These individuals were the same age and of similar weight. It is possible that these differences could be accounted for by differences in gastrointestinal transit time. Calcium is absorbed in the duodenum and the proximal segment of the small intestine; a smaller percentage is absorbed in the more distal segments of the small intestine (1) . Absorption may be influenced by hypocalcemia, pregnancy and lactation, and conditions which increase the rate and extent of absorption (1) . The F of calcium, in the form of calcium carbonate, has been reported to be between 9 and 37% (7). A highly variable F has been noted with commercially available calcium carbonate products (9) . Thus, a large proportion of calcium remains in the gastrointestinal tract and may have a prolonged availability for potential interaction with quinolones.
Under ideal circumstances of drug absorption and with healthy volunteers, we did not observe a change in ciprofloxacin F resulting from staggered doses of calcium carbonate. It is not possible to accurately infer the effects of this 
